ACOX1 and metabolic dysfunction-associated steatotic liver disease: Honda et al. demonstrated improvements in obesity, dyslipidemia, and histological markers of NAFLD in two rodent models of NASH using permafibrate treatment, with increased hepatic expression of acyl-CoA oxidase 1 (ACOX1) and uncoupling protein 3 (UCP3) [113].